Discover how the new McDonald criteria use imaging biomarkers such as the Central Vein Sign (CVS) to make earlier, more accurate MS diagnosis
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Over 750 industry clinical trials have been initiated for...
The imaging clinical trials industry continues to grow in the face of unique challenges! To help you keep up, we’ve put together the top trends to...
QMENTA's neuroimaging platform enables Parkinson's disease research through AI-powered MRI and PET biomarker analysis — including iron accumulation,...
Learn how to integrate AI tools into medical imaging workflows using QMENTA's cloud platform — covering benefits of AI in imaging, key challenges,...
QMENTA’s AI Platform Selected for the CAVS-MS Multiple Sclerosis Biomarker...